CRSP
Crispr Therapeutics AGNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$4.96B
P/E Ratio
—
EPS
$-6.47
Beta
1.79
52W High
$78.48
52W Low
$33.03
50-Day MA
$51.71
200-Day MA
$56.22
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
23.36
PEG Ratio
-0.21
About Crispr Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.
Fundamentals
| Revenue (TTM) | $3.51M |
| Gross Profit (TTM) | $-494.78M |
| EBITDA | $-548.84M |
| Operating Margin | -17912.00% |
| Return on Equity | -30.20% |
| Return on Assets | -15.80% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $20.04 |
| Price-to-Book | 2.58 |
| Price-to-Sales (TTM) | 1414.35 |
| EV/Revenue | 84.52 |
| EV/EBITDA | 14.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -97.60% |
| Shares Outstanding | $95.98M |
| Float | $95.55M |
| % Insiders | 4.88% |
| % Institutions | 73.28% |
Historical Volatility
HV 10-Day
50.80%
HV 20-Day
49.31%
HV 30-Day
66.38%
HV 60-Day
67.14%
HV Rank
53.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($83.35 target)
5
Strong Buy12
Buy9
Hold1
SellData last updated: 4/10/2026